Polyrizon Ltd. Overview
Pro stress-test →Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. The company's proprietary Capture and Contain (C&C) hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays and potentially functions as a "biological mask" with a thin shield containment barrier in the nasal cavity.
Strategic Profile
Pro stress-test →The company develops products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients, with lead candidates including PL-14 (nasal allergies blocker), PL-15 (COVID-19), and PL-16 (influenza blockers). Recent pre-clinical research released in January 2026 demonstrated PL-14's significant allergen-blocking performance compared to standard comparators.
Competitive Landscape
Pro stress-test →Polyrizon operates in the intranasal drug delivery and nasal barrier protection space, competing against both established nasal allergy products (like hydroxypropyl methylcellulose-based formulations) and emerging biotech platforms developing similar barrier technologies. The company's hydrogel platform differentiates through its naturally occurring building blocks and multi-indication potential, though it remains pre-clinical and faces competition from larger pharma companies and better-funded biotech firms pursuing similar intranasal approaches.
Industry Context
Polyrizon Ltd. operates in Biotechnology - Intranasal Drug Delivery.
Key facts
Founded: N/A · Headquarters: Ra'anana, Israel · Employees: N/A · Revenue: N/A · Market cap: N/A